February 18, 2026
Factcheck.org recently published an article featuring Rena Conti, Associate Professor, Markets, Public Policy, and Law, discussing how The Trump administration has promoted its drug pricing efforts as delivering the lowest prices in the world, despite little evidence so far of broad, system-wide savings.
While some discounted cash prices exist through the TrumpRx program, particularly for drugs not typically covered by insurance, most Americans, especially those with insurance, have not seen meaningful reductions at the pharmacy. Much of the impact remains unclear due to limited transparency, ongoing negotiations, and the complexity of how drug prices are actually set and paid.
As Rena Conti explains, “With rare exception, [these deals] don’t appear to have translated into actual savings for people at the pharmacy counter or for public or commercial payers yet,” underscoring the gap between headline claims and real-world impact.
Ultimately, without clearer policy details and broader structural changes, these efforts are unlikely to deliver the widespread cost relief being promised to consumers.
